Golimumab in patients affected by moderate to severe psoriatic arthritis: an open-label study in thirty-two patients previously treated with other biologics.

Abstract

BACKGROUND:

Clinical trials have demonstrated the efficacy of golimumab (GLB) in improving the signs and symptoms of psoriatic arthritis (PsA).

OBJECTIVE:

The aim of this study was to evaluate the efficacy of GLB in monotherapy in patients affected by PsA with cutaneous involvement unresponsive to other anti-tumor necrosis factor-α (TNF-α) agents.

METHODS:

This study included 32 patients treated with GLB as monotherapy, at a dosage of 50 mg, subcutaneously, every 4 weeks. Patients were divided into 3 groups (A, B, and C) according to their number of previous anti-TNF-α treatments (1, 2, or 3). Clinical and laboratory evaluations were performed at weeks 0, 12, and 24.

RESULTS:

All patients showed significant improvement of their clinical, inflammatory, and quality of life indexes.

CONCLUSION:

Data suggest that GLB can be successful and safe in patients affected by PsA with skin involvement previously treated with other anti-TNF-α agents.

• Authors: Maria Sole Chimenti, Miriam Teoli, Rosita Saraceno, Annunziata Dattola, Alessandra Ventura, Andrea Chiricozzi, Carlo Chiaramonte, Roberto Perricone, Sergio Chimenti
• Journal: Dermatology (Basel, Switzerland) (Dermatology) Vol. 227 Issue 4 Pg. 305-10 ( 2013) ISSN: 1421-9832 [Electronic] Switzerland
• PMID: 24280959 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antirheumatic Agents
• Biological Factors
• Tumor Necrosis Factor-alpha
• golimumab

Topics

• Adolescent
• Adult
• Aged
• Antibodies, Monoclonal (adverse effects, therapeutic use)
• Antirheumatic Agents (adverse effects, therapeutic use)
• Arthritis, Psoriatic (drug therapy)
• Biological Factors (therapeutic use)
• Female
• Humans
• Male
• Middle Aged
• Prospective Studies
• Severity of Illness Index
• Tumor Necrosis Factor-alpha (antagonists & inhibitors)
• Young Adult